Hekman C M, Loskutoff D J
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.
Arch Biochem Biophys. 1988 Apr;262(1):199-210. doi: 10.1016/0003-9861(88)90182-8.
Plasminogen activator inhibitor 1 (PAI-1) was purified from medium conditioned by cultured bovine aortic endothelial cells by successive chromatography on concanavalin A Sepharose, Sephacryl S-200, Blue B agarose, and Bio-Gel P-60. As shown previously for conditioned media (C. M. Hekman and D. J. Loskutoff (1985) J. Biol. Chem. 260, 11581-11587) the purified PAI-1 preparation contained latent inhibitory activity which could be stimulated 9.4-fold by sodium dodecyl sulfate and 45-fold by guanidine-HCl. The specific activity of the preparation following treatment with 0.1% sodium dodecyl sulfate was 2.5 X 10(3) IU/mg. The reaction between purified, guanidine-activated PAI-1 and both urokinase and tissue plasminogen activator (tPA) was studied. The second-order rate constants (pH 7.2, 35 degrees C) for the interaction between guanidine-activated PAI-1 and urokinase (UK), and one- and two-chain tPA are 1.6 X 10(8), 4.0 X 10(7), and 1.5 X 10(8) M-1 S-1, respectively. The presence of CNBr fibrinogen fragments had no affect on the rate constants of either one- or two-chain tPA. Steady-state kinetic analysis of the effect of PAI-1 on the rate of plasminogen activation revealed that the initial UK/PAI-1 interaction can be competed with plasminogen suggesting that the UK/PAI-1 interaction may involve a competitive type of inhibition. In contrast, the initial tPA/PAI-1 interaction can be competed only partially with plasminogen, suggesting that the tPA/PAI-1 interaction may involve a mixed type of inhibition. The results indicate that PAI-1 interacts more rapidly with UK and tPA than any PAI reported to date and suggest that PAI-1 is the primary physiological inhibitor of single-chain tPA. Moreover, the interaction of PAI-1 with tPA differs from its interaction with UK, and may involve two sites on the tPA molecule.
纤溶酶原激活物抑制剂1(PAI - 1)是从培养的牛主动脉内皮细胞的条件培养基中通过依次在伴刀豆球蛋白A琼脂糖凝胶、Sephacryl S - 200、蓝色琼脂糖凝胶和Bio - Gel P - 60上进行层析而纯化得到的。如先前针对条件培养基所显示的那样(C.M.赫克曼和D.J.洛斯库托夫(1985年)《生物化学杂志》260,11581 - 11587),纯化的PAI - 1制剂含有潜在的抑制活性,该活性可被十二烷基硫酸钠刺激9.4倍,被盐酸胍刺激45倍。用0.1%十二烷基硫酸钠处理后该制剂的比活性为2.5×10³ IU/mg。研究了纯化的、经胍激活的PAI - 1与尿激酶和组织纤溶酶原激活物(tPA)之间的反应。在pH 7.2、35℃条件下,经胍激活的PAI - 1与尿激酶(UK)、单链和双链tPA相互作用的二级速率常数分别为1.6×10⁸、4.0×10⁷和1.5×10⁸ M⁻¹ s⁻¹。CNBr纤维蛋白原片段的存在对单链或双链tPA的速率常数均无影响。对PAI - 1对纤溶酶原激活速率影响的稳态动力学分析表明,最初的UK/PAI - 1相互作用可被纤溶酶原竞争,这表明UK/PAI - 1相互作用可能涉及竞争性抑制类型。相反,最初的tPA/PAI - 1相互作用仅能被纤溶酶原部分竞争,这表明tPA/PAI - 1相互作用可能涉及混合型抑制。结果表明,PAI - 1与UK和tPA的相互作用比迄今报道的任何PAI都更快,并且表明PAI - 1是单链tPA的主要生理性抑制剂。此外,PAI - 1与tPA的相互作用不同于其与UK的相互作用,并且可能涉及tPA分子上的两个位点。